CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers will present data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry that enhance the understanding of PNH and provide important information for the medical community on the long-term management of the disease, including the continued benefits of ongoing Soliris® (eculizumab) treatment regardless of transfusion history.
Help employers find you! Check out all the jobs and post your resume.
